Has resourcing of non-governmental harm-reduction organizations in Ukraine improved HIV prevention and treatment outcomes for people who inject drugs? Findings from multiple bio-behavioural surveys.
Adult
Anti-HIV Agents
/ therapeutic use
Condoms
Cross-Sectional Studies
Delivery of Health Care
Female
Financing, Organized
/ organization & administration
HIV Infections
/ complications
Harm Reduction
Health Surveys
Humans
Male
Prevalence
Substance Abuse, Intravenous
/ complications
Syringes
Treatment Outcome
Ukraine
/ epidemiology
HIV
NGO
Ukraine
harm reduction
hepatitis C virus
prevention
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
04
03
2020
revised:
03
07
2020
accepted:
15
07
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
14
5
2021
Statut:
ppublish
Résumé
People who inject drugs (PWID) in Ukraine have high prevalences of HIV and hepatitis C (HCV). Since the turn of the century, various organizations have funded non-governmental organizations (NGOs) in Ukraine to provide PWID with needles and syringes, condoms, HIV and HCV testing, and improve linkage to opioid agonist therapy (OAT) and HIV treatment. We investigated whether contact with these NGOs was associated with improved HIV prevention and treatment outcomes among PWID. Five rounds of respondent-driven sampled integrated bio-behavioural survey data (2009 [N = 3962], 2011 [N = 9069], 2013 [N = 9502], 2015 [N = 9405], and 2017 [N = 10076]) among PWID in Ukraine (including HIV/HCV testing and questionnaires) were analysed using mixed-effect logistic regression models (mixed-effects: city, year). These regression models assessed associations between being an NGO client and various behavioural, OAT, HIV testing and HIV treatment outcomes, adjusting for demographic characteristics (age, gender, lifetime imprisonment, registration in a drug abuse clinic, education level). We also assessed associations between being an NGO client and being HIV positive or HCV positive, likewise adjusting for demographic characteristics (as above). NGO clients were more likely to have received HIV testing ever (adjusted odds ratio [aOR] 5.37, 95% confidence interval [95% CI]: 4.97 to 5.80) or in the last year (aOR 3.37, 95% CI: 3.20 to 3.54), to have used condoms at last sexual intercourse (aOR 1.37, 95% CI: 1.30 to 1.44) and sterile needles at last injection (aOR 1.37, 95% CI: 1.20 to 1.56), to be currently (aOR 4.19, 95% CI: 3.48 to 5.05) or ever (aOR 2.52, 95% CI: 2.32 to 2.74) on OAT, and to have received syringes (aOR 109.89, 95% CI: 99.26 to 121.66) or condoms (aOR 54.39, 95% CI: 50.17 to 58.96) in the last year. PWID who were HIV positive (aOR 1.40, 95% CI: 1.33 to 1.48) or HCV positive (aOR 1.57, 95% CI: 1.49 to 1.65) were more likely to have contact with NGOs, with HIV positive PWID in contact with NGOs being more likely to be registered at AIDS centres (aOR 2.34, 95% CI: 1.88 to 2.92) and to be on antiretroviral therapy (aOR 1.60, 95% CI: 1.40 to 1.83). Contact with PWID targeted NGOs in Ukraine is associated with consistently better preventive, HIV testing and HIV treatment outcomes, suggesting a beneficial impact of harm reduction NGO programming.
Identifiants
pubmed: 32851812
doi: 10.1002/jia2.25608
pmc: PMC7450208
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25608Subventions
Organisme : NIAID NIH HHS
ID : R01 AI147490
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA033679
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : CDC HHS
Pays : United States
Informations de copyright
© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Drug Alcohol Depend. 2019 May 1;198:80-86
pubmed: 30884432
Int J Drug Policy. 2019 May;67:91-101
pubmed: 30503695
J Viral Hepat. 2019 Dec;26(12):1388-1403
pubmed: 31392812
BMC Med Res Methodol. 2019 Oct 29;19(1):202
pubmed: 31664912
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
Addiction. 2018 Mar;113(3):545-563
pubmed: 28891267
Int J Drug Policy. 2018 Jul;57:11-17
pubmed: 29655101
Hepatol Med Policy. 2017 Jun 13;2:9
pubmed: 30288322
AIDS Behav. 2017 Jan;21(1):283-291
pubmed: 27272742
PLoS One. 2013;8(3):e59643
pubmed: 23527238
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):435-444
pubmed: 30981685
Int J Drug Policy. 2017 May;43:7-15
pubmed: 28160736
Lancet HIV. 2020 Feb;7(2):e121-e128
pubmed: 31879250
Lancet Infect Dis. 2016 Dec;16(12):1385-1398
pubmed: 27665254
BMJ. 2012 Oct 03;345:e5945
pubmed: 23038795
Sex Transm Dis. 2006 Oct;33(10 Suppl):S89-102
pubmed: 16735956
Lancet HIV. 2018 Jun;5(6):e276
pubmed: 29893242
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1051-1056
pubmed: 29339468
Addiction. 2019 Jan;114(1):150-166
pubmed: 30035835
AIDS. 2017 May 15;31(8):1181-1190
pubmed: 28323752
Lancet. 2016 Apr 2;387(10026):1427-1480
pubmed: 27021149
Lancet HIV. 2018 Oct;5(10):e578-e587
pubmed: 30033374
Lancet. 2016 Sep 17;388(10050):1228-48
pubmed: 27427455
Lancet HIV. 2016 Oct;3(10):e482-9
pubmed: 27658879
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
Addiction. 2019 Mar;114(3):560-570
pubmed: 30674091